A breakthrough year for vitamin C therapy I'm very excited to report that 2008 may turn out to be a breakthrough year for vitamin C therapy - also known as intravenous ascorbic acid (IAA) - in the treatment of cancer. About a year and a half ago I told you about a University of Kansas trial that was about to get underway. In that study, UK researchers planned to test IAA on ovarian cancer patients. That trial has been completed and the published results will be available later this year. And you can be sure I'll fill you in on the details as soon as the study is available. Meanwhile, researchers at Philadelphia's Thomas Jefferson University have launched a trial in which 20 non-Hodgkin lymphoma patients will receive IAA. As I've noted in previous e-Alerts, high doses of vitamin C administered by injection prompts production of hydrogen peroxide, which attacks cancer cells but leaves healthy cells undamaged. This is a very promising field of cancer study that has been neglected for much too long. You can read about several IAA case studies in which vitamin C therapy produced dramatic results in the e-Alert "Just Getting Started" (4/11/06), at this link: http://www.hsibaltimore.com/ealerts/ea200604/ea20060411.html And if you know someone who might benefit from IAA therapy, you can find orthomolecular practitioners who administer IAA at Orthomolecular.org. Just choose "Resources" in the main menu. Source:
"Jefferson Scientists Studying the Effects of High-Dose Vitamin C on Non-Hodgkin Lymphoma Patients" Press release from Thomas Jefferson University, 1/2/08, eurekalert.org | 
